TAS::75 0849::TAS "TOPIC 293, A LIQUID BIOPSY TO ASSESS MUTATION IN LUNG CANCER"

实体组织肿瘤患者治疗结果的改善取决于S针对导致肿瘤生长的基因突变的能力。目前，突变分析需要侵入性组织活检，而重复进行这在临床上是不切实际的。或者，提取循环肿瘤细胞(CTC)--由原发肿瘤释放到血流中的癌细胞--用于分子分析，为对特定患者的肿瘤和突变进行基因分型提供了一个有吸引力的策略。该项目的目标是展示和验证一种将高效微流控捕获与集成DNA扩增相结合的程序，以允许直接检测肺癌模型中的驱动程序突变。突变分析程序的重复性和准确性将在添加的样本中得到验证。此外，将对该程序进行测试，以详细说明用于捕获添加和临床样本中的四氯化碳的表面标记。这样，程序的灵活性也将得到评估。这将从根本上实现个性化医学中癌症预测测试的技术，并应用于许多实体肿瘤模型。

Improvement of treatment outcomes for patients with solid tissue tumors depends on the drug¿s ability to target the genetic mutations responsible for tumor growth. Currently, mutational analysis requires an invasive tissue biopsy, which is clinically impractical to perform repeatedly. Alternatively, extracting Circulating Tumor Cells (CTC) - cancer cells released into the bloodstream by the primary tumor - for molecular analysis offers an attractive strategy for genotyping patient-specific tumors and mutations. The goal of this project is to demonstrate and validate a procedure that marries high efficiency microfluidic capture with integrated DNA amplification to allow direct detection of the driver mutations in a lung cancer model. The reproducibility and accuracy of the mutation profiling procedure will be validated in spiked samples. Furthermore, the procedure will be tested to elaborate the surface markers used to capture CTC in spiked and clinical samples. In this way, the flexibility of the procedure will also be assessed. This will produce a fundamentally enabling technology for predictive cancer tests in personalized medicine with application in many solid tumor models.